DCX

Across TCGA pan-cancer cohorts, DCX mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated DCX data layer compared with 25 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DCX mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DCX expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC and UCEC are the cancer types where DCX mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.979	0.732	<.001	70	view →
UCEC	OS	Tertile	III,IV	0.478	0.847	.020	8	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

DCX–PDAC (OS)

Open the PDAC breakdown →